Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1

Fusobacterium nucleatum is a Gram-negative oncobacterium that is associated with colorectal cancer. The molecular mechanisms utilized by F. nucleatum to promote colorectal tumor development have largely focused on adhesin-mediated binding to the tumor tissue and on the pro-inflammatory capacity of F...

Full description

Saved in:
Bibliographic Details
Main Authors: Coco Duizer, Moniek Salomons, Merel van Gogh, Sanne Gräve, Freke A. Schaafsma, Maaike J. Stok, Merel Sijbranda, Raghuvandhanan Kumarasamy Sivasamy, Rob J. L. Willems, Marcel R. de Zoete
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Gut Microbes
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/19490976.2025.2458203
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832581987668328448
author Coco Duizer
Moniek Salomons
Merel van Gogh
Sanne Gräve
Freke A. Schaafsma
Maaike J. Stok
Merel Sijbranda
Raghuvandhanan Kumarasamy Sivasamy
Rob J. L. Willems
Marcel R. de Zoete
author_facet Coco Duizer
Moniek Salomons
Merel van Gogh
Sanne Gräve
Freke A. Schaafsma
Maaike J. Stok
Merel Sijbranda
Raghuvandhanan Kumarasamy Sivasamy
Rob J. L. Willems
Marcel R. de Zoete
author_sort Coco Duizer
collection DOAJ
description Fusobacterium nucleatum is a Gram-negative oncobacterium that is associated with colorectal cancer. The molecular mechanisms utilized by F. nucleatum to promote colorectal tumor development have largely focused on adhesin-mediated binding to the tumor tissue and on the pro-inflammatory capacity of F. nucleatum. However, the exact manner in which F. nucleatum promotes inflammation in the tumor microenvironment and subsequent tumor promotion remains underexplored. Here, we show that both living F. nucleatum and sterile F. nucleatum-conditioned medium promote CXCL8 release from the intestinal adenocarcinoma HT-29 cell line. We determined that the observed pro-inflammatory effect was ALPK1-dependent in both HEK293 and HT-29 cells and that the released F. nucleatum molecule had characteristics that match those of the pro-inflammatory ALPK1 ligand ADP-heptose or related heptose phosphates. In addition, we determined that not only F. nucleatum promoted an ALPK1-dependent pro-inflammatory environment but also other Fusobacterium species such as F. varium, F. necrophorum and F. gonidiaformans generated similar effects, indicating that ADP-heptose or related heptose phosphate secretion is a conserved feature of the Fusobacterium genus. By performing transcriptional analysis of ADP-heptose stimulated HT-29 cells, we found several inflammatory and cancer-related pathways to be differentially regulated, including DNA mismatch repair genes and the immune inhibitory receptor PD-L1. Finally, we show that stimulation of HT-29 cells with F. nucleatum resulted in an ALPK1-dependent upregulation of PD-L1. These results aid in our understanding of the mechanisms by which F. nucleatum can affect tumor development and therapy and pave the way for future therapeutic approaches.
format Article
id doaj-art-d0b77385b062452599c6fa74f3e71de7
institution Kabale University
issn 1949-0976
1949-0984
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Gut Microbes
spelling doaj-art-d0b77385b062452599c6fa74f3e71de72025-01-30T07:25:32ZengTaylor & Francis GroupGut Microbes1949-09761949-09842025-12-0117110.1080/19490976.2025.2458203Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1Coco Duizer0Moniek Salomons1Merel van Gogh2Sanne Gräve3Freke A. Schaafsma4Maaike J. Stok5Merel Sijbranda6Raghuvandhanan Kumarasamy Sivasamy7Rob J. L. Willems8Marcel R. de Zoete9Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, The NetherlandsFusobacterium nucleatum is a Gram-negative oncobacterium that is associated with colorectal cancer. The molecular mechanisms utilized by F. nucleatum to promote colorectal tumor development have largely focused on adhesin-mediated binding to the tumor tissue and on the pro-inflammatory capacity of F. nucleatum. However, the exact manner in which F. nucleatum promotes inflammation in the tumor microenvironment and subsequent tumor promotion remains underexplored. Here, we show that both living F. nucleatum and sterile F. nucleatum-conditioned medium promote CXCL8 release from the intestinal adenocarcinoma HT-29 cell line. We determined that the observed pro-inflammatory effect was ALPK1-dependent in both HEK293 and HT-29 cells and that the released F. nucleatum molecule had characteristics that match those of the pro-inflammatory ALPK1 ligand ADP-heptose or related heptose phosphates. In addition, we determined that not only F. nucleatum promoted an ALPK1-dependent pro-inflammatory environment but also other Fusobacterium species such as F. varium, F. necrophorum and F. gonidiaformans generated similar effects, indicating that ADP-heptose or related heptose phosphate secretion is a conserved feature of the Fusobacterium genus. By performing transcriptional analysis of ADP-heptose stimulated HT-29 cells, we found several inflammatory and cancer-related pathways to be differentially regulated, including DNA mismatch repair genes and the immune inhibitory receptor PD-L1. Finally, we show that stimulation of HT-29 cells with F. nucleatum resulted in an ALPK1-dependent upregulation of PD-L1. These results aid in our understanding of the mechanisms by which F. nucleatum can affect tumor development and therapy and pave the way for future therapeutic approaches.https://www.tandfonline.com/doi/10.1080/19490976.2025.2458203Fusobacterium nucleatumADP-heptoseALPK1PD-L1colorectal cancerimmune checkpoint inhibitor therapy
spellingShingle Coco Duizer
Moniek Salomons
Merel van Gogh
Sanne Gräve
Freke A. Schaafsma
Maaike J. Stok
Merel Sijbranda
Raghuvandhanan Kumarasamy Sivasamy
Rob J. L. Willems
Marcel R. de Zoete
Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1
Gut Microbes
Fusobacterium nucleatum
ADP-heptose
ALPK1
PD-L1
colorectal cancer
immune checkpoint inhibitor therapy
title Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1
title_full Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1
title_fullStr Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1
title_full_unstemmed Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1
title_short Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1
title_sort fusobacterium nucleatum upregulates the immune inhibitory receptor pd l1 in colorectal cancer cells via the activation of alpk1
topic Fusobacterium nucleatum
ADP-heptose
ALPK1
PD-L1
colorectal cancer
immune checkpoint inhibitor therapy
url https://www.tandfonline.com/doi/10.1080/19490976.2025.2458203
work_keys_str_mv AT cocoduizer fusobacteriumnucleatumupregulatestheimmuneinhibitoryreceptorpdl1incolorectalcancercellsviatheactivationofalpk1
AT monieksalomons fusobacteriumnucleatumupregulatestheimmuneinhibitoryreceptorpdl1incolorectalcancercellsviatheactivationofalpk1
AT merelvangogh fusobacteriumnucleatumupregulatestheimmuneinhibitoryreceptorpdl1incolorectalcancercellsviatheactivationofalpk1
AT sannegrave fusobacteriumnucleatumupregulatestheimmuneinhibitoryreceptorpdl1incolorectalcancercellsviatheactivationofalpk1
AT frekeaschaafsma fusobacteriumnucleatumupregulatestheimmuneinhibitoryreceptorpdl1incolorectalcancercellsviatheactivationofalpk1
AT maaikejstok fusobacteriumnucleatumupregulatestheimmuneinhibitoryreceptorpdl1incolorectalcancercellsviatheactivationofalpk1
AT merelsijbranda fusobacteriumnucleatumupregulatestheimmuneinhibitoryreceptorpdl1incolorectalcancercellsviatheactivationofalpk1
AT raghuvandhanankumarasamysivasamy fusobacteriumnucleatumupregulatestheimmuneinhibitoryreceptorpdl1incolorectalcancercellsviatheactivationofalpk1
AT robjlwillems fusobacteriumnucleatumupregulatestheimmuneinhibitoryreceptorpdl1incolorectalcancercellsviatheactivationofalpk1
AT marcelrdezoete fusobacteriumnucleatumupregulatestheimmuneinhibitoryreceptorpdl1incolorectalcancercellsviatheactivationofalpk1